Literature DB >> 19430671

Acute acquired toxoplasmosis: clinical-laboratorial aspects and ophthalmologic evaluation in a cohort of immunocompetent patients.

E S Neves1, L N Bicudo, A L Curi, E Carregal, W F Bueno, R G Ferreira, M R Amendoeira, E Benchimol, O Fernandes.   

Abstract

Most cases of acute acquired toxoplasmosis (AAT) are oligosymptomatic and self-limited. Therefore, these infections rarely indicate treatment. Prospective studies of AAT patients are rare in the medical literature. The frequency of systemic manifestations has not been sufficiently studied. In order to search for risks factors for systemic and ocular involvement, 37 patients were submitted to a diagnostic investigative protocol. The most frequent findings were lymph node enlargement (94.6%), asthenia (86.5%), headache (70.3%), fever (67.6%) and weight loss (62.2%). Hepatomegaly and/or splenomegaly were present in 21.6% of cases (8/37). Liver transaminases were elevated in 11 patients (29.7%) and lactic dehydrogenase in 17 patients (45.9%). Anaemia was found in four patients (10.8%), leucopoenia in six patients (16.2%), lymphocytosis in 14 patients (37.8%) and thrombocytopenia in one patient (2.7%). Fundoscopic examination revealed retinochoroiditis in four patients (10.8%). No statistical association was found between any one morbidity and retinochoroiditis. Nevertheless, a significant association was found between the presence of more than eight morbidity features at evaluation and long-lasting disease. An ideal diagnostic protocol for AAT would include evidence of systemic involvement. Such a protocol could be used when planning treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19430671     DOI: 10.1590/s0074-02762009000200039

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  7 in total

1.  PCR-based diagnosis is not always useful in the acute acquired toxoplasmosis in immunocompetent individuals.

Authors:  Elizabeth Souza Neves; Otavio Melo Espíndola; André Curi; Maria Regina Amendoeira; Danielle Nascimento Rocha; Leonardo Henrique Ferreira Gomes; Letícia Cunha Guida
Journal:  Parasitol Res       Date:  2021-01-08       Impact factor: 2.289

2.  microRNA-155 Expression and Butyrylcholinesterase Activity in the Liver Tissue of Mice Infected with Toxoplasma gondii (Avirulent and Virulent Strains).

Authors:  Mona El-Sayad; Mohamed Abdel Rahman; Neveen Hussein; Rawda Abdel Aziz; Hend A El-Taweel; Naglaa Abd El-Latif
Journal:  Acta Parasitol       Date:  2021-04-11       Impact factor: 1.440

3.  Acquired Immunodeficiency Syndrome Presented as Atypical Ocular Toxoplasmosis.

Authors:  Elias Khalili Pour; Hamid Riazi-Esfahani; Nazanin Ebrahimiadib; Violet Zaker Esteghamati; Mohammad Zarei
Journal:  Case Rep Ophthalmol Med       Date:  2021-05-01

4.  Toxoplasma gondii infection and liver disease: a case-control study in a northern Mexican population.

Authors:  Cosme Alvarado-Esquivel; José Luis Torres-Berumen; Sergio Estrada-Martínez; Oliver Liesenfeld; Miguel Francisco Mercado-Suarez
Journal:  Parasit Vectors       Date:  2011-05-13       Impact factor: 3.876

5.  MIF participates in Toxoplasma gondii-induced pathology following oral infection.

Authors:  Marta G Cavalcanti; Jacilene S Mesquita; Kalil Madi; Daniel F Feijó; Iranaia Assunção-Miranda; Heitor S P Souza; Marcelo T Bozza
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

6.  Single nucleotide polymorphisms in the interferon gamma gene are associated with distinct types of retinochoroidal scar lesions presumably caused by Toxoplasma gondii infection.

Authors:  Ricardo Guerra Peixe; Marcela Santana Bastos Boechat; Alba Lucinia Peixoto Rangel; Rhônia França Gomes Rosa; Maria Luiza Petzl-Erler; Lilian M G Bahia-Oliveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-02       Impact factor: 2.743

7.  Drinking water source and human Toxoplasma gondii infection in the United States: a cross-sectional analysis of NHANES data.

Authors:  Whitney S Krueger; Elizabeth D Hilborn; Reagan R Converse; Timothy J Wade
Journal:  BMC Public Health       Date:  2014-07-10       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.